RUNX2 and prostate carcinoma: Compared with normal tissues, the RUNX2 expression increased in 13 tumors (bladder, brain, breast, colorectal, esophageal, head and neck, kidney, leukemia, liver, lung, melanoma, pancreatic, and prostate cancers) and decreased in 6 tumors (colorectal, gastric, kidney, leukemia, lymphoma, and prostate cancers) (Figure 1A, middle panel).